Brokerages expect Fluidigm Co. (NASDAQ:FLDM) to announce earnings of ($0.41) per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Fluidigm’s earnings. Fluidigm reported earnings of ($0.08) per share in the same quarter last year, which indicates a negative year over year growth rate of 412.5%. The business is scheduled to issue its next earnings results on Thursday, February 14th.
According to Zacks, analysts expect that Fluidigm will report full-year earnings of ($1.54) per share for the current financial year. For the next year, analysts forecast that the company will post earnings of ($1.47) per share. Zacks’ EPS averages are an average based on a survey of analysts that cover Fluidigm.
Get Fluidigm alerts: Fluidigm (NASDAQ:FLDM) last issued its quarterly earnings data on Thursday, November 1st. The medical research company reported ($0.38) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.18) by ($0.20). Fluidigm had a negative return on equity of 86.00% and a negative net margin of 50.46%. The business had revenue of $28.96 million for the quarter, compared to analysts’ expectations of $27.50 million.
A number of brokerages recently issued reports on FLDM. BidaskClub lowered shares of Fluidigm from a “buy” rating to a “hold” rating in a research report on Thursday, December 13th. Zacks Investment Research upgraded shares of Fluidigm from a “sell” rating to a “hold” rating in a research report on Friday, September 28th. Finally, Piper Jaffray Companies upgraded shares of Fluidigm from a “neutral” rating to an “overweight” rating in a research report on Friday, November 2nd.
NASDAQ FLDM traded up $0.56 during mid-day trading on Monday, reaching $7.90. 236,600 shares of the stock were exchanged, compared to its average volume of 230,255. Fluidigm has a 1-year low of $4.65 and a 1-year high of $8.69. The firm has a market cap of $288.63 million, a P/E ratio of -6.64 and a beta of 2.88. The company has a debt-to-equity ratio of 7.56, a quick ratio of 1.45 and a current ratio of 1.85.
In other news, insider Levin Capital Strategies, L.P. bought 34,896 shares of the firm’s stock in a transaction that occurred on Tuesday, October 9th. The shares were purchased at an average price of $7.29 per share, for a total transaction of $254,391.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink . In the last 90 days, insiders have purchased 1,157,175 shares of company stock worth $7,930,293. 2.20% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently made changes to their positions in the business. Campbell & CO Investment Adviser LLC acquired a new position in shares of Fluidigm in the 3rd quarter valued at $117,000. Fairpointe Capital LLC acquired a new position in shares of Fluidigm in the 2nd quarter valued at $238,000. Los Angeles Capital Management & Equity Research Inc. acquired a new position in shares of Fluidigm in the 2nd quarter valued at $240,000. Paloma Partners Management Co boosted its holdings in shares of Fluidigm by 234.7% in the 2nd quarter. Paloma Partners Management Co now owns 56,900 shares of the medical research company’s stock valued at $339,000 after purchasing an additional 39,900 shares during the last quarter. Finally, Jennison Associates LLC boosted its holdings in shares of Fluidigm by 70.8% in the 2nd quarter. Jennison Associates LLC now owns 68,791 shares of the medical research company’s stock valued at $410,000 after purchasing an additional 28,520 shares during the last quarter. Institutional investors own 98.32% of the company’s stock.
About Fluidigm
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system.
Featured Story: Are 12b-1 Fees Affecting Your Mutual Fund Performance?
Get a free copy of the Zacks research report on Fluidigm (FLDM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fluidigm analysts' ratings for Fluidigm and related companies daily email newsletter .
